<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>15</Volume>
				<Issue>14</Issue>
				<PubDate PubStatus="epublish">
					<Year>2014</Year>
					<Month>12</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Optimal Timing of Radiotherapy with Alternating/Sequential Radio-Chemotherapy for Limited-stage Small Cell Lung Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>5697</FirstPage>
			<LastPage>5699</LastPage>
			<ELocationID EIdType="pii">29483</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>&lt;br/&gt;&lt;b&gt;Objective&lt;/b&gt;: To investigate the optimal timing of radiotherapy with alternating/sequential radio-chemotherapyfor limited-stage small cell lung cancer (LS-SCLC). &lt;br/&gt;&lt;b&gt;Methods&lt;/b&gt;: 91 patients with LS-SCLC were retrospectivelyanalyzed and divided into two groups according to the number of chemotherapy cycles before radiotherapy.If the patient received radiotherapy after 3 cycles or fewer cycles of chemotherapy, classification was into theearly group, if not, into the late group. All patients received 6 cycles of standard chemotherapy (EP/EC) andconventional radiotherapy (56 gy~ 60 gy/28 f ~30 f). &lt;br/&gt;&lt;b&gt;Results&lt;/b&gt;: The response rate (RR) of the early and late groupswere 85.7% and 81.6%, respectively, with no significant difference (p&gt;0.05). In contrast, the progression-freesurvival (PFS) in the early group was better than that in the late group (11.8 months vs 9.86 months), and thedifference was significant (p&lt;0.05). There was no significant difference between two groups in adverse reactions,which gastrointestinal irritation and bone marrow suppression being the most common (p&gt;0.05). &lt;br/&gt;&lt;b&gt;Conclusions&lt;/b&gt;:Radiotherapy after 3 cycles or fewer cycles of chemotherapy does not bring significant benefits for RR of patientswith LS-SCLC, but it could significantly prolong their PFS without increase in adverse reactions.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">Carcinoma</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">small cell lung cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">Chemotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">radiotherapy</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">timing</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_29483_1fd33ca9efb3f6c43bf872d5ac6ea6ab.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
